About CRISPR Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800
Debt
Debt-to-Equity RatioN/A
Current Ratio17.12%
Quick Ratio17.12%
Price-To-Earnings
Trailing P/E Ratio-31.62
Forward P/E Ratio-19.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$41 million
Price / Sales62.21
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book13.22
Profitability
EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-166.74%
Return on Equity-35.07%
Return on Assets-23.15%
Miscellaneous
Employees127
Outstanding Shares47,170,000
CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is CRISPR Therapeutics' stock symbol?
CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were CRISPR Therapeutics' earnings last quarter?
CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.02. The firm had revenue of $2.39 million for the quarter, compared to analysts' expectations of $3.61 million. CRISPR Therapeutics had a negative return on equity of 35.07% and a negative net margin of 166.74%. The company's quarterly revenue was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.77) earnings per share. View CRISPR Therapeutics' Earnings History.
When is CRISPR Therapeutics' next earnings date?
What price target have analysts set for CRSP?
9 analysts have issued 1-year price targets for CRISPR Therapeutics' stock. Their predictions range from $51.00 to $86.00. On average, they anticipate CRISPR Therapeutics' share price to reach $63.95 in the next twelve months. View Analyst Ratings for CRISPR Therapeutics.
What are Wall Street analysts saying about CRISPR Therapeutics stock?
Here are some recent quotes from research analysts about CRISPR Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (3/13/2018)
- 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
- 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)
Are investors shorting CRISPR Therapeutics?
CRISPR Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,403,752 shares, an increase of 74.9% from the February 28th total of 1,374,219 shares. Based on an average trading volume of 1,434,160 shares, the days-to-cover ratio is presently 1.7 days. Currently, 12.4% of the company's stock are short sold.
Who are some of CRISPR Therapeutics' key competitors?
Some companies that are related to CRISPR Therapeutics include Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), Cellectis (CLLS), REGENXBIO (RGNX) and Adaptimmune Therapeutics (ADAP).
Who are CRISPR Therapeutics' key executives?
CRISPR Therapeutics' management team includes the folowing people:
- Dr. Rodger Novak, Founder & Chairman (Age 51)
- Mr. Marc A. Becker, Former CFO & Sr. VP (Age 46)
- Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
- N. Anthony Coles Jr., Sr. Advisor (Age 58)
- Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
When did CRISPR Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.
Has CRISPR Therapeutics been receiving favorable news coverage?
Media coverage about CRSP stock has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CRISPR Therapeutics earned a media sentiment score of 0.14 on Accern's scale. They also assigned news coverage about the company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of CRISPR Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CRISPR Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $54.07.
How big of a company is CRISPR Therapeutics?
CRISPR Therapeutics has a market capitalization of $2.71 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. CRISPR Therapeutics employs 127 workers across the globe.
How can I contact CRISPR Therapeutics?
CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.
MarketBeat Community Rating for CRISPR Therapeutics (CRSP)
MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
CRISPR Therapeutics (NASDAQ:CRSP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. Their average twelve-month price target is $63.95, suggesting that the stock has a possible upside of 18.27%. The high price target for CRSP is $86.00 and the low price target for CRSP is $51.00. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.63 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $63.95 | $53.5333 | $22.8125 | $23.0833 |
| Price Target Upside: | 18.27% upside | 0.31% downside | 10.50% downside | 23.18% upside |
CRISPR Therapeutics (NASDAQ:CRSP) Consensus Price Target History
CRISPR Therapeutics (NASDAQ:CRSP) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
CRISPR Therapeutics (NASDAQ:CRSP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
CRISPR Therapeutics (NASDAQ CRSP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 39.98%
Institutional Ownership Percentage: 26.50%
CRISPR Therapeutics (NASDAQ CRSP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/16/2018 | Tyler Dylan-Hyde | Insider | Sell | 66,000 | $28.03 | $1,849,980.00 | 25,204 |  |
| 1/5/2018 | Aktiengesellschaft Bayer | Major Shareholder | Buy | 527,472 | $22.75 | $11,999,988.00 | | |
| 1/5/2018 | Kurt Von Emster | Director | Sell | 92,337 | $26.96 | $2,489,405.52 | | |
| 1/2/2018 | Kurt Von Emster | Director | Sell | 37,754 | $26.76 | $1,010,297.04 | | |
| 1/2/2018 | Tyler Dylan-Hyde | Insider | Sell | 38,000 | $21.64 | $822,320.00 | 70,204 | |
| 12/29/2017 | Tyler Dylan-Hyde | Insider | Sell | 31,000 | $22.72 | $704,320.00 | | |
| 12/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 700 | $21.75 | $15,225.00 | 115,904 | |
| 12/22/2017 | Thomas Woiwode | Director | Sell | 3,059 | $20.29 | $62,067.11 | 4,959 | |
| 12/22/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $20.55 | $308,250.00 | 115,204 | |
| 12/15/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.90 | $283,500.00 | 130,204 | |
| 12/4/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 1,112,446 | $18.98 | $21,114,225.08 | | |
| 12/1/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 87,991 | $19.10 | $1,680,628.10 | | |
| 11/29/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 4,263 | $19.25 | $82,062.75 | | |
| 11/27/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 27,990 | $19.75 | $552,802.50 | | |
| 11/27/2017 | Thomas Woiwode | Director | Sell | 200 | $20.24 | $4,048.00 | 8,218 | |
| 11/24/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 26,010 | $20.00 | $520,200.00 | | |
| 11/24/2017 | Thomas Woiwode | Director | Sell | 1,700 | $20.21 | $34,357.00 | 8,218 | |
| 11/22/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 256,000 | $19.76 | $5,058,560.00 | | |
| 11/20/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 158,718 | $19.02 | $3,018,816.36 | | |
| 11/17/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 51,282 | $18.44 | $945,640.08 | | |
| 11/15/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 15,000 | $17.67 | $265,050.00 | | |
| 11/13/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 65,093 | $17.76 | $1,156,051.68 | | |
| 11/10/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 10,000 | $17.28 | $172,800.00 | | |
| 11/8/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 16,875 | $18.06 | $304,762.50 | | |
| 11/6/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 79,327 | $18.89 | $1,498,487.03 | | |
| 11/3/2017 | Corp /De/ Celgene | Major Shareholder | Sell | 22,759 | $19.10 | $434,696.90 | | |
| 9/5/2017 | Rodger Novak | CEO | Sell | 18,470 | $20.76 | $383,437.20 | 1,148,007 | |
| 8/30/2017 | Rodger Novak | CEO | Sell | 75,795 | $20.25 | $1,534,848.75 | 1,232,697 | |
| 8/30/2017 | Samarth Kulkarni | Insider | Sell | 27,154 | $20.08 | $545,252.32 | 110,893 | |
| 8/28/2017 | Kurt Von Emster | Director | Sell | 88,011 | $19.79 | $1,741,737.69 | | |
| 8/25/2017 | Kurt Von Emster | Director | Sell | 22,781 | $19.42 | $442,407.02 | | |
| 8/23/2017 | Kurt Von Emster | Director | Sell | 17,989 | $18.53 | $333,336.17 | | |
| 8/21/2017 | Kurt Von Emster | Director | Sell | 3,150 | $18.52 | $58,338.00 | | |
| 8/17/2017 | Kurt Von Emster | Director | Sell | 34,141 | $19.06 | $650,727.46 | | |
| 8/15/2017 | Kurt Von Emster | Director | Sell | 55,569 | $19.59 | $1,088,596.71 | | |
| 8/8/2017 | Kurt Von Emster | Director | Sell | 35,473 | $18.63 | $660,861.99 | | |
| 8/8/2017 | Tyler Dylan-Hyde | Insider | Sell | 15,000 | $18.57 | $278,550.00 | 167,727 | |
| 8/4/2017 | Kurt Von Emster | Director | Sell | 50,477 | $17.81 | $898,995.37 | | |
| 8/1/2017 | Kurt Von Emster | Director | Sell | 5,512 | $17.51 | $96,515.12 | | |
| 7/28/2017 | Kurt Von Emster | Director | Sell | 41,312 | $17.63 | $728,330.56 | | |
| 7/26/2017 | Kurt Von Emster | Director | Sell | 32,930 | $17.60 | $579,568.00 | | |
| 7/14/2017 | Kurt Von Emster | Director | Sell | 69,859 | $16.84 | $1,176,425.56 | | |
| 7/12/2017 | Kurt Von Emster | Director | Sell | 31,992 | $16.56 | $529,787.52 | | |
| 7/5/2017 | Kurt Von Emster | Director | Sell | 4,254 | $16.26 | $69,170.04 | | |
| 6/29/2017 | Kurt Von Emster | Director | Sell | 43,202 | $16.90 | $730,113.80 | | |
| 6/27/2017 | Kurt Von Emster | Director | Sell | 81,435 | $17.08 | $1,390,909.80 | | |
| 6/23/2017 | Kurt Von Emster | Director | Sell | 32,368 | $16.23 | $525,332.64 | | |
| 6/22/2017 | Rodger Novak | CEO | Sell | 10,825 | $15.37 | $166,380.25 | 1,225,830 | |
| 6/21/2017 | Rodger Novak | CEO | Sell | 30,222 | $15.01 | $453,632.22 | 1,230,397 | |
| 6/9/2017 | Rodger Novak | CEO | Sell | 5,303 | $15.02 | $79,651.06 | 1,219,208 | |
| 5/30/2017 | Rodger Novak | CEO | Sell | 3,650 | $15.02 | $54,823.00 | 1,218,655 | |
| 5/17/2017 | Rodger Novak | CEO | Sell | 50,000 | $16.26 | $813,000.00 | 1,239,082 | |
| 5/5/2017 | Rodger Novak | CEO | Sell | 616 | $16.92 | $10,422.72 | 1,215,621 | |
| 5/4/2017 | Rodger Novak | CEO | Sell | 49,384 | $16.30 | $804,959.20 | 1,230,929 | |
| 4/28/2017 | Tyler Dylan-Hyde | Insider | Sell | 21,639 | $16.78 | $363,102.42 | 180,495 | |
| 4/27/2017 | Samarth Kulkarni | Insider | Sell | 5,481 | $16.76 | $91,861.56 | 137,322 | |
| 4/25/2017 | Samarth Kulkarni | Insider | Sell | 11,615 | $16.78 | $194,899.70 | 137,047 | |
| 4/20/2017 | Rodger Novak | CEO | Sell | 50,000 | $17.88 | $894,000.00 | 1,262,711 | |
| 4/20/2017 | Tyler Dylan-Hyde | Insider | Sell | 10,177 | $17.71 | $180,234.67 | 200,274 | |
| 10/24/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,150 | $14.00 | $11,202,100.00 | | |
| 10/24/2016 | Simeon George | Director | Buy | 66,500 | $14.00 | $931,000.00 | | |
(Data available from 1/1/2013 forward)
CRISPR Therapeutics (NASDAQ CRSP) News Headlines
| Source: |
|
CRISPR Therapeutics (NASDAQ:CRSP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
CRISPR Therapeutics (NASDAQ:CRSP) Income Statement, Balance Sheet and Cash Flow Statement
CRISPR Therapeutics (NASDAQ CRSP) Stock Chart for Saturday, April, 21, 2018
Loading chart…
